Verified Nov 2026
Electronics & Software
·
Irvine, California
·
Since 2015
Beta Bionics is a medical device company headquartered in Irvine, California, founded in 2015 and publicly traded on NASDAQ under the ticker BBNX. It has an employee band of 200-500 and a reported revenue band of $100.3M. The company makes the iLet Bionic Pancreas, an autonomous insulin delivery system for people with diabetes, and serves the medical and diabetes care sector. In September 2026 it announced an agreement to integrate the iLet and mint systems with Senseonics' Eversense 365 continuous glucose monitor.
Beta Bionics at a glance
Revenue
100.3M
Employees
200-500
Founded
2015
Headquarters
Irvine, California
Ownership
Publicly traded (NASDAQ: BBNX)
Import activity
49
Industries
Automotive
Electric Vehicles
Electronics
Medical
Plumbing & Hardware
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
49
Named foreign suppliers
14
Top origins
Belgium · Colombia · Portugal · Netherlands
Shared foreign counterparties do not establish that these companies buy from Beta Bionics.
What this tells a buyer
Beta Bionics announced a $172.5 million public offering of common stock in September 2026, with the offering closing on September 17, 2026.
Its products include an insulin pump and a sensor, with the iLet Bionic Pancreas designed for users aged six and older and operating without carbohydrate input.
The company is publicly listed on NASDAQ (BBNX) and reported its third quarter 2026 financial results on October 27, 2026.
Source: US customs bill-of-lading records and public filings · Last verified Nov 05, 2026
Overview
Beta Bionics is a medical device company headquartered in Irvine, California, founded in 2015 and publicly traded on NASDAQ under the ticker BBNX. It has an employee band of 200-500 and a reported revenue band of $100.3M. The company makes the iLet Bionic Pancreas, an autonomous insulin delivery system for people with diabetes, and serves the medical and diabetes care sector. In September 2026 it announced an agreement to integrate the iLet and mint systems with Senseonics' Eversense 365 continuous glucose monitor.
At a glance
Attribute | Detail |
|---|---|
Founded | 2015 |
Headquarters | Irvine, California |
Employees | 200-500 |
Revenue | 100.3M |
Ownership | Publicly traded (NASDAQ: BBNX) |
Primary capability | Electronics & Software |
What Beta Bionics makes
Its products include an insulin pump and a sensor, with the iLet Bionic Pancreas designed for users aged six and older and operating without carbohydrate input.
Products and capabilities described on the company's own site include Pump, Sensor (source: betabionics.com).
Trade and customs footprint
Beta Bionics announced a $172.5 million public offering of common stock in September 2026, with the offering closing on September 17, 2026. US customs bill-of-lading records list 49 inbound shipments across 14 foreign suppliers, with top origins including Belgium · Colombia · Portugal · Netherlands.
Latest developments
2026-11-03 — News | Beta Bionics, Inc. (betabionics.com)
2026-10-27 — Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance | Tue, 10/27/2026 - 16:02 (betabionics.com)
2026-09-22 — Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365 | Tue, 09/22/2026 - 07:30 (betabionics.com)
2026-09-17 — Beta Bionics Announces Closing of $172.5 Million Public Offering of Common Stock | Thu, 09/17/2026 - 16:05 (betabionics.com)
2026-09-15 — Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock | Tue, 09/15/2026 - 16:14 (betabionics.com)
2026-09-14 — Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm | Mon, 09/14/2026 - 07:30 (betabionics.com)
Company details
The company is publicly listed on NASDAQ (BBNX) and reported its third quarter 2026 financial results on October 27, 2026. Beta Bionics was founded in 2015, has an estimated 200-500 employees, and is headquartered in Irvine, California.
Frequently asked questions
What does Beta Bionics make?
Beta Bionics is a medical device company headquartered in Irvine, California, founded in 2015 and publicly traded on NASDAQ under the ticker BBNX. It has an employee band of 200-500 and a reported revenue band of $100.3M. The company makes the iLet Bionic Pancreas, an autonomous insulin delivery system for people with diabetes, and serves the medical and diabetes care sector. In September 2026 it announced an agreement to integrate the iLet and mint systems with Senseonics' Eversense 365 continuous glucose monitor.
Where is Beta Bionics headquartered?
Beta Bionics is headquartered in Irvine, California (11 Hughes, Irvine, California, 92618-1902).
When was Beta Bionics founded?
Beta Bionics was founded in 2015.
How big is Beta Bionics?
Beta Bionics has an estimated 200-500 employees, with revenue in the 100.3M range.
Is Beta Bionics publicly traded?
Publicly traded (NASDAQ: BBNX). Public financial figures are drawn from its filings.
Does Beta Bionics import from overseas suppliers?
US customs bill-of-lading records show 49 inbound shipments for Beta Bionics, with top origins including Belgium · Colombia · Portugal · Netherlands.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.